Lesson plan

ML-007

ML-007 is a selective muscarinic acetylcholine M 1 and M 4 receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias. It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC). The drug is taken orally. It produces antipsychotic-like effects in rodents, including inhibition of amphetamine and phencyclidine (PCP)-induced hyperlocomotion and activity in the conditioned avoidance response test. These effects appear to dependent on activation of both muscarinic acetylcholine M 1 and M 4 receptors. The drug is approximately 10-fold more potent than xanomeline in these tests. As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias. It is under development by MapLight Therapeutics. The drug is a small molecule, but its chemical structure does not seem to have been disclosed.

Back to article

Article summary

ML-007 is a selective muscarinic acetylcholine M 1 and M 4 receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias. It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC). The drug is taken orally. It produces antipsychotic-like effects in rodents, including inhibition of amphetamine and phencyclidine (PCP)-induced hyperlocomotion and activity in the conditioned avoidance response test. These effects appear to dependent on activation of both muscarinic acetylcholine M 1 and M 4 receptors. The drug is approximately 10-fold more potent than xanomeline in these tests. As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias. It is under development by MapLight Therapeutics. The drug is a small molecule, but its chemical structure does not seem to have been disclosed.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.